Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) ROCE %: 26.76% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJSE:920735 Jiangsu Deyuan Pharmaceutical Co Ltd BJSE:920735
97 GF Score
Price ¥26.66
GF Value ¥29.63
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Jiangsu Deyuan Pharmaceutical Co ROCE %?

Jiangsu Deyuan Pharmaceutical Co BJSE:920735 97 ROCE % is 26.76% as of Jun. 2026. GuruFocus rates BJSE:920735 with a GF Score™ of 97/100 and a GF Value™ of ¥29.63 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jiangsu Deyuan Pharmaceutical Co's annualized ROCE % for the quarter that ended in Jun. 2026 was 26.76%.

Jiangsu Deyuan Pharmaceutical Co  (BJSE:920735) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jiangsu Deyuan Pharmaceutical Co ROCE % Related Terms

Jiangsu Deyuan Pharmaceutical Co ROCE % Historical Data

* Premium members only.

The historical data trend for Jiangsu Deyuan Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Deyuan Pharmaceutical Co ROCE % Chart

Jiangsu Deyuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.51 17.55 16.03 18.60 21.02

Jiangsu Deyuan Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.07 22.77 21.57 19.08 26.76
BJSE:920735
97GF Score
Jiangsu Deyuan Pharmaceutical Co Ltd BJSE:920735
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Deyuan Pharmaceutical Co ROCE % Calculation

Jiangsu Deyuan Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=267.004/( ( (1384.414 - 222.232) + (1571.094 - 192.269) )/ 2 )
=267.004/( (1162.182+1378.825)/ 2 )
=267.004/1270.5035
=21.02 %

Jiangsu Deyuan Pharmaceutical Co's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=382.676/( ( (1653.402 - 259.278) + (1710.596 - 244.426) )/ 2 )
=382.676/( ( 1394.124 + 1466.17 )/ 2 )
=382.676/1430.147
=26.76 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 26.76% mean?
Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) has a ROCE % of 26.76% as of Jun. 2026.
Is Jiangsu Deyuan Pharmaceutical Co's ROCE % too high?
Jiangsu Deyuan Pharmaceutical Co's current ROCE % is 26.76%. The Drug Manufacturers industry median ROCE % is 6.63. Jiangsu Deyuan Pharmaceutical Co's value of 26.76% is 303.6% above this industry median. Overall, Jiangsu Deyuan Pharmaceutical Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Deyuan Pharmaceutical Co's ROCE % compare to ZTS?
Jiangsu Deyuan Pharmaceutical Co's ROCE % of 26.76% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 6.63. Jiangsu Deyuan Pharmaceutical Co's value of 26.76% is 303.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 6.63, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Deyuan Pharmaceutical Co's current ROCE % of 26.76% is 303.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 6.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Deyuan Pharmaceutical Co's current ROCE % is 26.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Deyuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.63, compared to a current price of ¥26.66 — trading 10% below its estimated fair value. The current ROCE % is 26.76% and 303.6% above the Drug Manufacturers industry median of 6.63. Jiangsu Deyuan Pharmaceutical Co's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Jiangsu Deyuan Pharmaceutical Co (BJSE:920735), the current ROCE % is 26.76% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Deyuan Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥26.66 is trading 10% below its estimated GF Value™ of ¥29.63. GuruFocus considers Jiangsu Deyuan Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for BJSE:920735:

  • ROCE %: 26.76%
  • GF Value™: ¥29.63 vs. price of ¥26.66 (10% below fair value)
  • GF Score™: 97/100 with 2 warning signs
  • Industry Position: 303.6% above the Drug Manufacturers median

No single metric tells the full story. See the BJSE:920735 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jiangsu Deyuan Pharmaceutical Co Business Description

Address No. 29, Changjiang Road, Economic and Technological Development Zone, Jiangsu Province, Lianyungang, CHN, 222047
Jiangsu Deyuan Pharmaceutical Co Ltd is involved in research and development, production and sales of tablets, hard capsules, and raw materials.
97GF Score

Get the complete analysis for BJSE:920735

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.66
Price
¥29.63
GF Value